Key highlights in NHL: updates in MCL, the role of transplantation, and novel bispecific antibodies
Автор: VJHemOnc – Video Journal of Hematology & HemOnc
Загружено: 2022-12-21
Просмотров: 143
Описание:
Michael Dickinson, MBBS, DMedSc, FRACP, FRACPA, Peter MacCallum Cancer Centre, Melbourne, Australia, and Tycel Phillips, MD, City of Hope, Duarte, CA, share some key updates in non-Hodgkin lymphoma (NHL) presented at the 2022 ASH Annual Meeting. The experts first discuss clinical trial updates in mantle cell lymphoma (MCL), highlighting results from the TRIANGLE trial (NCT02858258), and further debate the role of Bruton's tyrosine kinase (BTK) inhibitors in the frontline treatment of MCL. Following this, Dr Dickinson and Dr Phillips comment on the changing role of transplantation in NHL, and then go on to discuss data on the use of glofitamab in relapsed/refractory (R/R) MCL and aggressive large B-cell lymphoma (LBCL). To conclude, the experts further comment on the growing role of bispecific antibodies, and share their thoughts on where these agents may fit along with CAR-T cell therapy in the NHL treatment armamentarium. This discussion took place at the 64th ASH Annual Meeting and Exposition congress held in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Повторяем попытку...
Доступные форматы для скачивания:
Скачать видео
-
Информация по загрузке:
